NCT01854125

Autologous Mesenchymal Stem Cell Transplantation in Cirrhosis Patients With Refractory Ascites

Efficacy of Autologous Mesenchymal Stem Cell Transplantation Via Liver Artery in Liver Cirrhosis Patients With Refractory Ascites

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Nanjing PLA General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Liver cirrhosis (LC) is the final destiny in chronic liver disease.The quality of life in liver cirrhosis patients with refractory ascites are very wretched. The objective of this study is to evaluate the therapeutic efficacy of autologous bone marrow mesenchymal stem cells (BMSCs) transplantation via liver artery in Child-Pugh B and C stage of liver cirrhosis patients with refractory ascites. The immunomodulatory impact of MSCs in fibrosis was confirmed, and several clinical studies have applied MSCs to eliminate the progression of fibrosis. In this research the investigators will study the affect and influence of MSCs in the patients,include assay of liver function,variation of ascites,Child-Pugh score etc.

Conditions

• Immune Function in Blood
• Liver Function in Blood
• Variation of Ascites
• Characters of Quality of Life
• Child-Pugh Score

Interventions

Type	Name	Description
BIOLOGICAL	autologous bone marrow mesenchymal stem cells transplantation	Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
BIOLOGICAL	autologous bone marrow msenchymal stem cells transplantation

Timeline

• Start date: 2013-05-01
• Primary completion: 2014-01-01
• First posted: 2013-05-15
• Last updated: 2013-05-15

Locations

1 site across 1 country: China